Haleon plc
General ticker "HLNCF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $44.9B (TTM average)
Haleon plc does not follow the US Stock Market performance with the rate: -17.5%.
Estimated limits based on current volatility of 2.7%: low 5.06$, high 5.35$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2025-08-15, amount 0.03$ (Y1.15%)
- Total employees count: 24622 as of 2022
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.00$, 6.22$]
- 2025-12-31 to 2026-12-31 estimated range: [4.21$, 6.54$]
Financial Metrics affecting the HLNCF estimates:
- Positive: with PPE of 23.7 at the end of fiscal year the price was very low
- Positive: Operating profit margin, % of 19.64 > 18.34
- Positive: 6.66 < Operating cash flow per share per price, % of 6.70
- Positive: Investing cash flow per share per price, % of 1.54 > -0.63
- Negative: negative Industry operating cash flow (median)
- Positive: 42.77 < Shareholder equity ratio, % of 47.11 <= 64.37
- Negative: 0.73 < Interest expense per share per price, % of 1.15
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of -1.58 <= -0.18
Short-term HLNCF quotes
Long-term HLNCF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | £10,858.00MM | £11,302.00MM | £11,233.00MM |
| Operating Expenses | £9,033.00MM | £9,306.00MM | £9,027.00MM |
| Operating Income | £1,825.00MM | £1,996.00MM | £2,206.00MM |
| Non-Operating Income | £-207.00MM | £-368.00MM | £-296.00MM |
| Interest Expense | £278.00MM | £414.00MM | £394.00MM |
| R&D Expense | £300.00MM | £311.00MM | £298.00MM |
| Income(Loss) | £1,618.00MM | £1,628.00MM | £1,910.00MM |
| Taxes | £499.00MM | £517.00MM | £435.00MM |
| Profit(Loss)* | £1,060.00MM | £1,049.00MM | £1,442.00MM |
| Stockholders Equity | £16,331.00MM | £16,606.00MM | £16,166.00MM |
| Inventory | £1,348.00MM | £1,408.00MM | £1,190.00MM |
| Assets | £34,815.00MM | £34,055.00MM | £34,315.00MM |
| Operating Cash Flow | £2,063.00MM | £2,100.00MM | £2,301.00MM |
| Capital expenditure | £328.00MM | £336.00MM | £318.00MM |
| Investing Cash Flow | £-8,784.00MM | £-134.00MM | £528.00MM |
| Financing Cash Flow | £6,911.00MM | £-1,568.00MM | £-1,537.00MM |
| Earnings Per Share** | £0.11 | £0.11 | £0.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.